Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
First-in-human study listings include EOS-215 and RO7673396.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.